1. Mylan data on file (myl_xen_dof_v1).
  2. Xenidate XL. Summary of Product Characteristics (SPC) – all doses. April 2017.
  3. NICE. Methylphenidate hydrochloride. (last accessed 27.09.18).
  4. Mylan data on file (tablet sizes).
  5. NICE Clinical Knowledge Summaries. Attention deficit hyperactivity disorder.!topicsummary (last accessed 11.10.18).
  6. Holden SE et al. The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child and Adolescent Psychiatry and Mental Health 2013;7:34.
  7. Xenidate XL. Patient Information Leaflets – all doses. April 2017.
  8. NHS. Symptoms: Attention deficit hyperactivity disorder (ADHD). hyperactivity-disorder-adhd/symptoms/ (last accessed 09.10.18).
  9. NICE guideline 87. Attention deficit hyperactivity disorder: diagnosis and management.
    14 March 2018. (last accessed 12.10.18).
  10. NHS England. Medicines Value Programme. (last accessed 12.20.18).